Cannovum AG signs supply agreement for medical cannabis with Aurora Europe

DGAP-News: Cannovum AG / Key word (s): Product Launch

06/24/2021 / 09:06
The issuer is solely responsible for the content of this announcement.

Cannovum AG (Düsseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21) has concluded a long-term supply contract with Aurora through its licensed subsidiary Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.

The Canadian company Aurora is one of the largest authorized manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017, Aurora entered the German market with the takeover of the German company Pedanios, making Aurora / Pedanios products one of the first cannabis medicinal products available in Germany. This enabled doctors and pharmacists to gain experience in treating their patients with these products.
The expansion of the medical cannabis portfolio to include the entire Aurora product range is therefore an important step towards the best possible patient care for Cannovum.

“We want to support doctors and pharmacists in finding the right treatment for their patients. To do this, we need to offer a full portfolio of medical cannabis that gives them the ability to fully customize therapy. Through the partnership with Aurora we are confident that we will continue to offer high quality drugs to ensure the best therapy for every patient, ”says Pia Marten, CEO of Cannovum AG.

Cannovum’s own pharmaceutical representative team was trained intensively in the new products in order to confidently advise pharmacists and doctors.


Linda Rasch, IR & PR, Cannovum AG
Telephone +49 30 3982 163 62,

Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific training and all-encompassing sales for simplified and easier access to cannabis-based therapies.

More information is available at

06/24/2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP sales services include regulatory notices, financial / corporate news and press releases.
Archive on

Source link

You May Also Like